Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 17/20 | 0.45 |
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | IL6 | P05231 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5801773 | 0.86 | NR3C1 (0.37) | NR3C1CYP3A4PGRNR3C2CYP2C9 | |
| SCHEMBL4223561 | 0.85 | NR3C1 (0.35) | NR3C1CYP3A4PGRNR3C2KCNH2 | |
| SCHEMBL3709591 | 0.84 | NR3C1 (0.50) | NR3C1CYP3A4PGRNR3C2KCNH2 | |
| SCHEMBL3826673 | 0.82 | NR3C1 (0.39) | NR3C1CYP3A4PGR | |
| SCHEMBL3714468 | 0.81 | NR3C1 (0.50) | NR3C1CYP3A4PGRNR3C2 | |
| SCHEMBL3752102 | 0.81 | NR3C1 (0.43) | NR3C1CYP3A4PGRNR3C2KCNH2 | |
| SCHEMBL5798392 | 0.79 | NR3C1 (0.54) | NR3C1CYP3A4PGRNR3C2CYP2C9 | |
| SCHEMBL3707342 | 0.79 | NR3C1 (0.45) | NR3C1CYP3A4PGRNR3C2 | |
| SCHEMBL3655671 | 0.78 | LOXL2 (0.40) | NR3C1PGRNR3C2CYP2D6 | |
| SCHEMBL4044983 | 0.77 | NR3C1 (0.60) | NR3C1CYP3A4PGRNR3C2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051710-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | Bausch & Lomb Incorporated (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008021729-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1673088-A1 | 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |